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1384Objective: The detection rates of small lung cancers, especially adenocarcinoma, have recently increased. An
understanding of malignant aggressiveness is critical for the selection of suitable therapeutic strategies, such as
sublobar resection. The objective of this study was to examine the malignant biological behavior of clinical stage
IA adenocarcinoma and to select therapeutic strategies using high-resolution computed tomography,
fluorodeoxyglucose-positron emission tomography/computed tomography, and a pathologic analysis in the set-
ting of a multicenter study.
Methods: We performed high-resolution computed tomography and fluorodeoxyglucose-positron emission to-
mography/computed tomography in 502 patients with clinical T1N0M0 adenocarcinoma before they underwent
surgery with curative intent. We evaluated the relationships between clinicopathologic characteristics and maxi-
mum standardized uptake values on fluorodeoxyglucose-positron emission tomography/computed tomography,
ground-glass opacity ratio, and tumor disappearance rate on high-resolution computed tomography and component
of bronchioloalveolar carcinoma on surgical specimens, as well as between these and surgical findings. We used
a phantom study to correct the serious limitation of anymulti-institution study using positron emission tomography/
computed tomography, namely, a discrepancy in maximum standardized uptake values among institutions.
Results: Analyses of receiver operating characteristic curves identified an optimal cutoff value to predict high-
grade malignancy of 2.5 for revised maximum standardized uptake values, 20% for ground-glass opacity ratio,
30% for tumor disappearance rate, and 30% for bronchioloalveolar carcinoma ratio. Maximum standardized
uptake values and bronchioloalveolar carcinoma ratio, tumor disappearance rate, and ground-glass opacity ratio
mirrored the pathologic aggressiveness of tumor malignancy, nodal metastasis, recurrence, and prognosis,
including disease-free and overall survival.
Conclusions:Maximum standardized uptake value is a significant preoperative predictor for surgical outcomes.
High-resolution computed tomography and fluorodeoxyglucose-positron emission tomography/computed to-
mography findings are important to determine the appropriateness of sublobar resection for treating clinical
stage IA adenocarcinoma of the lung. (J Thorac Cardiovasc Surg 2011;141:1384-91)Earn CME credits at
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The Journal of Thoracic and Cardiovascular SurThe standard treatment for operable non–small cell lung
cancer, even early clinical T1N0M0 disease, remains lobec-
tomy with dissection of the hilar and mediastinal lymph
nodes.1 However, clinical investigations to date have dem-
onstrated that sublobar resection, which chiefly consists of
radical segmentectomy with nodal dissection, might be fea-
sible for treating early lung cancers with the tangible advan-
tages of maintained lung function and a reasonable
prognosis.2,3 To date, there are no means to preoperatively
identify early lung cancers that are biologically less
aggressive and may be better suited for a sublobar resection.
Recent advances in high-resolution computed tomogra-
phy (HRCT) and the widespread application of computed
tomography (CT) screening have enhanced the discovery
of small lung cancers, particularly adenocarcinoma.2,3
These early-stage cancers are biologically heterogeneous,
and the malignant aggressiveness is not well characterizedgery c June 2011
FIGURE 1. maxSUVadjusted using experimental phantom (revised max-
SUV). Original maxSUV data were calibrated by multiplying calibration
factors based on phantom studies to correct inter-institutional SUV vari-
ability. MaxSUV ratio is expressed as maxSUVof each institute for max-
SUV of control institute (Institute 1). maxSUV, Maximum standardized
uptake value.
Abbreviations and Acronyms
AUC ¼ area under the curve
BAC ¼ bronchioloalveolar carcinoma
CT ¼ computed tomography
DFS ¼ disease-free survival
FDG ¼ F-18 fluorodeoxyglucose
FOV ¼ field of view
GGO ¼ ground-glass opacity
HRCT ¼ high-resolution computed
tomography
maxSUV ¼ maximum standardized uptake value
PET ¼ positron emission tomography
ROC ¼ receiver operating characteristic
SUV ¼ standardized uptake value
TDR ¼ tumor disappearance rate
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Sat the time of diagnosis. This information should be consid-
ered in selecting the therapeutic strategy.
Positron emission tomography (PET)/CT with F-18
fluorodeoxyglucose (FDG) has become an integral part of
the non–small cell lung cancer evaluation.4-6 This
modality generates quantitative images based on glucose
metabolism reflecting the metabolic activity and
proliferative potential of malignant tumors, and providing
anatomic CT images. Small-scale studies have demon-
strated the role of FDG-PET/CT in assessing the biological
status of cancers,7,8 but this requires confirmation in a larger
cohort. Therefore, assessed the biological nature of small
adenocarcinomas in more than 500 patients by using
HRCT and FDG-PET/CT and the pathologic findings of
surgical specimens in a multicenter setting. Because of the
heterogeneity of PET techniques and performance, we cor-
rected inter-institutional errors in maximum standardized
uptake values (maxSUVs) resulting from PET/CT scanners
of variable quality based on outcomes of a study using an an-
thropomorphic body phantom that conformed to National
Electrical Manufacturers Association standards.9PATIENTS AND METHODS
We enrolled 502 patients (female, 279 [56%]; male, 223 [44%]; mean
age, 65.3  9.6 years) with clinical T1N0M0 stage IA adenocarcinoma of
the lung at 4 institutions between August 1, 2005, and December 31, 2009.
All patients underwent HRCT and FDG-PET/CT followed by curative R0
resection. The ethics committees at each institution approved this multicen-
ter study and the prospective database used in the analysis.
High-Resolution Computed Tomography
Chest images were obtained using 16-row multidetector CT indepen-
dently of subsequent PET/CT examinations. High-resolution images of
the tumors were acquired using the following parameters: 120 kVp,
200 mA, 1- to 2-mm section thickness, 512 3 512 pixel resolution, 0.5-
to 1-second scanning time, a high spatial reconstruction algorithm with
a 20-cm field of view (FOV) and mediastinal (level, 40 HU; width, 400The Journal of Thoracic and CarHU) and lung (level, 600 HU; width, 1600 HU) window settings.
Ground-glass opacity (GGO) was defined as a misty increase in lung atten-
uation without obscuring the underlying vascular markings, and we defined
the GGO ratio (%) as [1 (maximum dimension of consolidation of lung
windows/maximum dimension of tumor of lung windows)]3 100. Tumor
disappearance rate (TDR) (%) was defined as [1(tumor area of the medi-
astinal windows/tumor area of the lung windows)] 3 100.2,3,10
Fluorodeoxyglucose-Positron Emission Tomography/
Computed Tomography
The patients fasted for more than 4 hours before being intravenously in-
jected with 74-370MBq of FDG, and then relaxed for at least 1 hour before
FDG-PET/CT scanning. Blood glucose was calculated before tracer injec-
tion to confirm a level of less than 150 mg/dL.11 Patients with blood
glucose values of 150 mg/dL or greater were excluded from PET/CT
acquisition. Images were obtained in this study using Discovery ST
(GE Healthcare, Buckinghamshire, England), Aquiduo (Toshiba Medical
Systems Corporation, Tochigi, Japan), or Biograph Sensation16 (Siemens
Healthcare, South Iselin, NJ) integrated PET/CT scanners. Low-dose unen-
hanced CT images of a 2- to 4-mm section thickness for attenuation correc-
tion and localization of lesions identified by PET were obtained from the
head to the pelvic floor of each patient using a standard protocol. Immedi-
ately after CT, PET covered the identical axial FOV for 2 to 4 minutes per
table position depending on the condition of the patient and scanner perfor-
mance. All PET images with a 50-cm FOV were reconstructed using an
iterative algorithm with CT-derived attenuation correction. Variations in
standardized uptake value (SUV) among institutions were minimized using
the anthropomorphic body phantom. A calibration factor was analyzed by
dividing the actual SUV by the gauged mean SUV in the phantom back-
ground to decrease inter-institutional SUV inconsistencies, and the final
maxSUV used in this is referred to as revised maxSUV. The adjustment
of the inter-institutional variability in SUV narrowed the range from 0.89
to 1.24 to 0.97 to 1.18 when maxSUV ratio was expressed as the maxSUV
of each institute for the maxSUVof the control institute (Figure 1).diovascular Surgery c Volume 141, Number 6 1385
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FIGURE 2. ROC curves for positive predictive values of pathologic lymph node metastasis, lymphatic invasion, blood vessel invasion, or pleural invasion.
ROC curves are for revised maxSUV (A), GGO ratio (B), TDR (C), and BAC ratio (D). maxSUV,Maximum standardized uptake value;GGO, ground-glass
opacity; TDR, tumor disappearance rate; BAC, bronchioloalveolar carcinoma; AUC, area under the curve; SUV, standardized uptake value.
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pathologically evaluated (including the largest cut) using hematoxylin–eo-
sin and Elastica van Gieson staining. The amount of bronchioloalveolar
carcinoma (BAC) areas proportionate to whole tumors was approximately
calculated as the BAC ratio. Independent observers and pathologists
blindly evaluated GGO and BAC ratios and TDR, and corrected discrep-
ancies among evaluations using mean values.
Receiver operating characteristic (ROC) curves of the revised maxSUV,
GGO ratios, TDR, and BAC ratios to predict lymphatic, blood vessel, and
pleural invasion or nodal involvement were generated to determine the cut-
off values that yielded optimal sensitivity and specificity. The patient pop-
ulation was subdivided on the basis of the cutoff values of the revised
SUVmax, GGO, TDR, and BAC ratios derived from ROC curves. We per-
formed multiple logistic regression analyses to demonstrate independent
variables of maxSUV, GGO ratio, TDR, and BAC ratio relative to the pre-
diction of pathologic findings for high malignant grade and recurrence.
Survival was calculated using the Kaplan–Meier method, and differences
were determined using the log-rank test. Disease-free survival (DFS) was
defined as time from date of surgery until the first event (relapse or death
from any cause) or last follow-up. Overall survival was defined as time
from the date of surgery until death from any cause or last follow-up.RESULTS
The primary tumor measured by HRCT was 20 mm or
less in diameter in 290 patients (58%) and 21 to 30 mm
in 212 patients (42%). Lymphatic permeation, blood vessel,
and pleural invasion was evident in 76 patients (15%), 92
patients (18%), and 56 patients (11%), respectively, and
lymph nodes were involved in 38 (8%) of them.1386 The Journal of Thoracic and Cardiovascular SurThe ROC curves identified optimal revised maxSUV,
GGO, TDR, and BAC ratio cutoff values of 2.5 (area under
the curve [AUC], 0.877), 20% (AUC, 0.858), 30% (AUC,
0.870), and 30% (AUC, 0.873), respectively, for predicting
pathologic findings of high malignancy (Figure 2). At a cut-
off value of 2.5, a high revised maxSUV significantly corre-
lated with male gender, a high CEA value, large tumor,
lymphatic invasion, vascular invasion, pleural invasion,
and lymph node metastasis (Table 1). Likewise, low TDR,
GGO, and BAC ratios were significantly associated with
a high CEA value, lymphatic, vascular, pleural invasion,
and lymph node metastasis. Possible predictors for lym-
phatic, vascular, and pleural invasion, and nodal metastasis
and recurrence were investigated (Table 2). Revised max-
SUV, GGO ratio, TDR, and BAC ratio were all significant
determinants for predicting lymphatic permeation, vascular
and pleural invasion, nodal metastasis, and recurrence.
However, the odds ratios indicated that revised maxSUV
and the BAC ratio revealed biological aggressive tumor
grade more effectively than GGO ratio and TDR.
A significant difference in DFS was identified (Figure 3)
between patients whose adenocarcinoma had revised max-
SUV 2.5 or less (n ¼ 343; 3-year DFS rate, 96%) and
greater than 2.5 (n ¼ 159; 3-year DFS rate, 77%;
P<.001). We also found significant differences in DFS be-
tween patients whose adenocarcinoma had GGO ratios ofgery c June 2011
TABLE 1. Clinical characteristics of patients with cT1N0M0 adenocarcinoma (n ¼ 502)
Patients
(n ¼ 502)
Revised maxSUV GGO ratio TDR BAC ratio
2.5/>2.5
(n ¼ 343/159)
P
value
20%/<20%
(n ¼ 304/198)
P
value
30%/<30%
(n ¼ 346/156)
P
value
30%/<30%
(n ¼ 304/198)
P
value
Age (y)
(means SD)
65.3  9.6 65.3  9.4/65.5 9.8 .8380 65.0  9.3/65.9  10.0 .2790 64.7  9.4/66.7  9.9 .0365 65.4  9.5/65.3  9.7 .9054
Gender
Male 223 140/83 .0169 119/104 .0032 144/79 .0597 113/110 <.0001
Female 279 203/76 185/94 202/77 191/88
CEA (ng/mL)
5 449 321/128 <.0001 289/160 <.0001 324/125 <.0001 284/165 .0003
>5 53 22/31 15/38 22/31 20/33
Tumor size (mm)
T 20 290 218/72 .0001 183/107 .1723 213/77 .0104 180/110 .4178
<20 T 30 212 125/87 121/91 133/79 124/88
Ly permeation
positive 76 15/61 <.0001 13/63 <.0001 25/51 <.0001 12/64 <.0001
negative 426 328/98 291/135 321/105 292/134
V invasion
positive 92 16/76 <.0001 15/77 <.0001 23/69 <.0001 11/81 <.0001
negative 410 327/83 289/121 323/87 293/117
P invasion
positive 56 12/44 <.0001 10/46 <.0001 14/42 <.0001 6/50 <.0001
negative 446 331/115 294/152 332/114 298/148
N metastasis
positive 38 10/28 <.0001 8/30 <.0001 10/28 <.0001 5/33 <.0001
negative 464 333/131 296/168 336/128 299/165
CEA, Carcinoembryonic antigen; Ly, lymphatic; V, blood vessel; P, pleural; N, lymph node; maxSUV, maximum standardized uptake value; GGO, ground-glass opacity; TDR,
tumor disappearance rate; BAC, bronchioloalveolar carcinoma.
TABLE 2. Analysis of possible predictors for Ly factor, V factor, P factor, N factor, and recurrence status
Factors total (n ¼ 502) Favorable Unfavorable Odds ratio (95% CI) P value
Positive Ly factor (n ¼ 76)
Revised maxSUV 2.5 >2.5 13.61 (7.41–25.01) <.0001
GGO ratio 20% <20% 10.45 (5.56–19.63) <.0001
TDR 30% <30% 6.24 (3.68–10.56) <.0001
BAC ratio 30% <30% 11.62 (6.07–22.25) <.0001
Positive V factor (n ¼ 92)
Revised maxSUV 2.5 >2.5 18.71 (10.37–33.78) <.0001
GGO ratio 20% <20% 12.26 (6.78–22.17) <.0001
TDR 30% <30% 11.14 (6.57–18.88) <.0001
BAC ratio 30% <30% 18.44 (9.48–35.87) <.0001
Positive P factor (n ¼ 56)
Revised maxSUV 2.5 >2.5 10.55 (5.39–20.68) <.0001
GGO ratio 20% <20% 8.90 (4.37–18.12) <.0001
TDR 30% <30% 8.74 (4.60–16.59) <.0001
BAC ratio 30% <30% 16.78 (7.03–40.03) <.0001
Positive N factor (n ¼ 38)
Revised maxSUV 2.5 >2.5 7.12 (3.36–15.07) <.0001
GGO ratio 20% <20% 6.61 (2.96–14.74) <.0001
TDR 30% <30% 7.35 (3.47–15.56) <.0001
BAC ratio 30% <30% 11.96 (4.58–31.22) <.0001
Positive recurrence (n ¼ 29)
Revised maxSUV 2.5 >2.5 7.71 (3.22–18.46) <.0001
GGO ratio 20% <20% 8.25 (3.09–22.01) <.0001
TDR 30% <30% 4.66 (2.11–10.28) <.0001
BAC ratio 30% <30% 10.84 (3.71–31.66) <.0001
Ly, Lymphatic permeation; V, blood vessel invasion; P, pleural invasion; N, lymph node metastasis; maxSUV, maximum standardized uptake value; GGO, ground-glass opacity;
TDR, tumor disappearance rate; BAC, bronchioloalveolar carcinoma.
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FIGURE 3. DFS curves according to grade of revised maxSUV (A), GGO ratio (B), TDR (C), and BAC ratio (D).maxSUV,Maximum standardized uptake
value; GGO, ground-glass opacity; TDR, tumor disappearance rate; BAC, bronchioloalveolar carcinoma.
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S20% or more (n¼ 304; 3-year DFS rate, 97%) and less than
20% (n ¼ 198; 3-year DFS rate, 80%; P<.001), between
those whose adenocarcinoma had TDR 30% or more
(n ¼ 346; 3-year DFS rate, 95%) and less than 30%
(n ¼ 156; 3-year DFS rate, 80%; P<.001) and betweenFIGURE 4. Overall survival curves according to grade of revised maxSUV (A
dardized uptake value; GGO, ground-glass opacity; TDR, tumor disappearance
1388 The Journal of Thoracic and Cardiovascular Surthose whose adenocarcinoma had BAC ratios of 30% or
more (n ¼ 304; 3-year DFS rate, 97%) and less than
30% (n ¼ 198; 3-year DFS rate, 80%; P<.001). Revised
maxSUV (P ¼ .016) and GGO (P ¼ .024) and pathologic
BAC (P ¼ .005) ratios were significant prognostic factors), GGO ratio (B), TDR (C), and BAC ratio (D). maxSUV, Maximum stan-
rate; BAC, bronchioloalveolar carcinoma.
gery c June 2011
TABLE 3. Relationship between ground-glass opacity/tumor disappearance rate and revisedmaxSUVas predictors for Ly factor, V factor, P factor,
N factor, and recurrence status
Revised
maxSUV
Ly permeation
(þ)/(-)
V invasion
(þ)/(-)
P invasion
(þ)/(-)
N metastasis
(þ)/(-)
Recurrence
(þ)/(-)
GGO 50% and TDR 50%
(n ¼ 259)
1.5
(n ¼ 48)
2/46
(4%)
1/47
(2%)
3/45
(6%)
0/48
(0)
0/48
(0)
<1.5 2.5
(n ¼ 68)
10/58
(15%)
14/54
(21%)
8/60
(12%)
8/60
(12%)
3/65
(4%)
2.5<
(n ¼ 143)
59/84
(41%)
73/70
(51%)
43/100
(30%)
27/116
(19%)
22/121
(15%)
>50% GGO or>50% TDR
(n ¼ 243)
1.5
(n ¼ 180)
2/178
(1%)
1/179
(1%)
0/180
(0)
1/179
(1%)
2/178
(1%)
<1.5 2.5
(n ¼ 47)
1/46
(2%)
0/47
(0)
1/46
(2%)
1/46
(2%)
2/45
(4%)
2.5<
(n ¼ 16)
2/14
(13%)
3/13
(19%)
1/15
(6%)
1/15
(6%)
0/16
(0)
maxSUV, Maximum standardized uptake value; Ly, lymphatic; V, blood vessel; P, pleural; N, lymph node; GGO, ground-glass opacity; TDR, tumor disappearance rate.
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ally significant (Figure 4).
We examined the relationships between HRCT findings
and maxSUV for predicting tumor invasiveness, nodal me-
tastasis, and recurrence (Table 3). Generally, solid tumors
on HRCT with GGO 50% or less and TDR 50% or less
had high maxSUV and were more frequently associatedFIGURE 5. Tumor (1.5 cm in diameter) located at right middle lobe. A, HRCT fi
Microscope findings show BAC with mucin formation (C and D, staining with
The Journal of Thoracic and Carwith high malignant grade, nodal metastasis, and recur-
rence. However, solid tumors with lower maxSUV were as-
sociated with low malignant grade and far less nodal
metastasis and recurrence. Among patients with tumors
showing GGO 50% or less and TDR 50% or less, 19%
and 15% of those with a revised maxSUV greater than
2.5 had nodal metastasis and recurrence, respectively,ndings showGGO ratio of 5%. B, PET/CT findings show no accumulation.
hematoxylin–eosin at 325 and 3200 magnification, respectively).
diovascular Surgery c Volume 141, Number 6 1389
FIGURE 6. Relationship between tumor size and revised maxSUV level
in cT1N0M0 adenocarcinomas. A, All patients. B, Tumor size  20 mm
and revised maxSUV  3.0. Nodal metastasis (triangles); recurrence
(rhombi); lymphatic, vascular, or pleural invasion without nodal metastasis
(squares). maxSUV,Maximum standardized uptake value; N, lymph node;
Ly, lymphatic; V, blood vessel; P, pleural.
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Swhereas those with tumors showing revised maxSUV 1.5 or
less had neither nodal metastasis nor recurrence.
DISCUSSION
The frequency of identifying small lung cancers has
recently increased since CT and enhanced scanning have
become routine procedures and surgeons have thus been
able to assess the advantages of sublobar resection, such
as radical segmentectomy instead of lobectomy.2,3 The
biological malignancy of small adenocarcinoma has
generally been evaluated on the basis of HRCT findings.
The specificity, sensitivity, and accuracy of radiologic1390 The Journal of Thoracic and Cardiovascular Surdiagnoses with HRCT on lymphatic/vessel invasion and
nodal involvement of clinical T1N0M0 adenocarcinoma
have been examined in a large prospective study
(JCOG0201).12 The conclusions failed to corroborate pre-
determined criteria using GGO ratio and TDR for specific-
ity, and thus applicants for radical sublobar resection could
not be suitably confirmed on the basis of criteria generated
fromHRCT findings. Therefore, the development of a novel
tool that surpasses the diagnostic ability of HRCT is a cur-
rent challenge.
Phase III randomized trials of standard lobectomy versus
experimental limited resection for small (2 cm in diameter)
peripheral non–small cell lung cancers are ongoing in the
United States (CALGB-140503) and in Japan (JCOG0802/
WJOG4607L). Because the biological behavior of several
types of small lung cancers is aggressive, to detect indolent
lung cancers preoperatively with radiographic imaging is
important for the standardization of sublobar resection, al-
though accurate radiographic definition of tumor extension
and metastasis is challenging. We previously demonstrated
that maxSUV on FDG-PET/CT is a potentially promising
parameter of the degree of malignancy among cT1N0M0
lung adenocarcinoma.7,8 However, relatively few patients
were analyzed and postoperative survival data were
obtained during a short period. We therefore performed an
extended, larger multicenter study. To our knowledge,
a large scale multi-institutional study of malignant tumor
grade analyzed using PET/CT has not been reported.
The present analyses revealed that adenocarcinoma with
high maxSUV and low GGO ratio, TDR, or BAC ratio is
more closely associated with lymphatic, vessel, pleural in-
vasion, lymph node metastasis, and recurrence. We also
found a closer association between serum CEA levels and
maxSUV, GGO ratio, TDR, and BAC ratio, which is preop-
eratively vital in uncovering patients at high risk of poten-
tial advanced disease.13,14 High maxSUV was also a poor
prognostic determinant for DFS and overall survival.
These outcomes suggested that maxSUV can be a realistic
surrogate marker of tumor malignancy grade and that
FDG-PET/CT in addition to HRCT is a potent prognostic
modality with which to detect patients at high risk of recur-
rence after curative resection of small adenocarcinoma.
Because PET/CT imaging reflects metabolic activity as
glucose metabolism whereas HRCT generates only ana-
tomic images, findings of PET/CT could be more powerful
clinical predictors of biological tumor performance than
those of HRCT. Most solid tumors on HRCT have high
maxSUVand aggressive malignant behavior, whereas solid
tumors with lower maxSUV were less aggressive. Figure 5
shows a mucinous BAC with indolent behavior that ap-
peared as a solid tumor on HRCT with no accumulation
on PET/CT.
We analyzed the association between tumor size and
maxSUV in cT1N0M0 adenocarcinoma (Figure 6). A largergery c June 2011
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Stumor was associated with a higher maximum SUV, and
both size and maxSUV can predict tumor invasiveness,
nodalmetastasis, and recurrence. The figures show a notable
tendency of small adenocarcinoma with high maxSUV to
have more malignant features than larger adenocarcinoma
with low maxSUV.
One of the major limitations of multicenter trials using
PET is the wide variation in SUV among institutions.
Many factors, such as preparation procedures, scan acquisi-
tion, image reconstruction, and data analysis affect
SUV,15,16 although semiquantitative SUV in patients with
cancer is extensively applied to diagnose, stage, and
evaluate therapeutic effectiveness.4-6 Westerterp and
colleagues17 reported that a discrepancy in SUV of up to
30% among institutions could create a significant problem
for multicenter studies. Inter-institutional variability in
SUV obtained in the present study was minimized using
an anthropomorphic body phantom. Therefore, quantitative
SUVs adjusted by phantom studies can be dependable, and
such correction will help to overcome one major limitation
of multicenter of PET studies.CONCLUSIONS
The findings of HRCTand FDG-PET/CTare important to
select therapeutic strategies for treating c-stage IA adeno-
carcinoma of the lung, and maxSUV on FDG-PET/CT is
an especially significant preoperative predictor for surgical
outcomes. Sublobar resection might be performed in pa-
tients with adenocarcinoma with maxSUV 1.5 or less, and
lymphadenectomy is required for tumors with maxSUV
greater than 1.5.References
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